Tobira Development (NASDAQ:TBRA) Getting Somewhat Favorable Press Coverage, Analysis Finds
Media coverage about Tobira Development (NASDAQ:TBRA) has trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tobira Development earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.6230271659849 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Tobira Development (TBRA) opened at $42.09 on Tuesday. Tobira Development has a twelve month low of $3.76 and a twelve month high of $42.33. The company has a debt-to-equity ratio of 0.44, a current ratio of 5.38 and a quick ratio of 5.38.
WARNING: “Tobira Development (NASDAQ:TBRA) Getting Somewhat Favorable Press Coverage, Analysis Finds” was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.mareainformativa.com/2018/01/30/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-tobira-development-tbra-share-price-updated-updated-updated.html.
Tobira Development Company Profile
Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.
Receive News & Ratings for Tobira Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development and related companies with MarketBeat.com's FREE daily email newsletter.